miR-300 has been reported to inhibit the epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer via targeting of Twist [48]; miR-300 has also been shown to be a negative regulator of differentiation in glioma stem-like cells [49], but its effect on VEGF-C expression remains largely unknown. The gene discussed is VEGFC; the disease is neoplasm.